The role of IrF-4 and IRF-8 in the Pathogenesis of B-cell neoplasm
IrF-4 和 IRF-8 在 B 细胞肿瘤发病机制中的作用
基本信息
- 批准号:18591092
- 负责人:
- 金额:$ 1.77万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (C)
- 财政年份:2006
- 资助国家:日本
- 起止时间:2006 至 2007
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
IRF-4 and IRF-8 are the transcription factors of IRF family playing the important role in the development of B-lymphocytes. The expression of IRF-4 has been recognized as one of the prognostic factor for diffuse large B-cell lymphoma (DL). On the other hands, the lack of IRF-8 induces myeloid leukemia. The aim of this study is to approach the question if these molecules act in the pathogenesis of B-cell malignancies. First of all, the expression of IRF-4 and IRF-8 was tested by semi-quantitative RT-PCR. Forty-two DL and 32 follicular lymphoma (FL) tumors were analyzed. Both IRF-4 and IRF-8 gene were detected in most samples. Higher IRF-8 expression than IRF-4 was seen in 13 DL samples (30.9%) and 16 in FL samples (69.5%). Interestingly, the overall survival was better in IRF-4<IRF-8 patients (statistically not significant). These results suggests that DL could be categorized based on the expression of these factors. Next, to identify protein of these factors directory in single tumor cell, immunohistochemistry was challenged. However, it was unable to gain the clear results because of the lack of good antibody for human IRF-8. Recently, IRF-4 and 8 are reported to cooperate with bc1-2 during the pathogenesis of hematological malignancies. Bcl-2 is an apoptotic factor forming chimera gene with IgH resulted by the translocation (14; 8) typically found in FL. Also, this protein is over expressed in high risk DL cells. To clarify the role of this translocation in DL, FISH for bcl2/IgH, as well as immunohistochemistry for bc1-2 protein were performed on 35 samples from high risk DL patients. Bc12/IgH fusion was detected in 57.1% of samples from dead cases. On the other hands, neither bc12/IgH fusion and bc1-2 expression was detected in 71.4% of tumor cells from survivors, suggesting that translocation (14; 18) plays key role in refractory DL.
IRF-4和IRF-8是IRF家族的转录因子,在B淋巴细胞的发育过程中起重要作用。IRF-4的表达被认为是弥漫性大B细胞淋巴瘤(DL)的预后因素之一。另一方面,IRF-8的缺乏诱导骨髓性白血病。本研究的目的是探讨这些分子是否在B细胞恶性肿瘤的发病机制中起作用。首先,采用半定量RT-PCR检测IRF-4和IRF-8的表达。分析了42例DL和32例滤泡性淋巴瘤(FL)肿瘤。在大多数样本中同时检测到IRF-4和IRF-8基因。在13例DL样本(30.9%)和16例FL样本(69.5%)中观察到IRF-8表达高于IRF-4。有趣的是,IRF-4<IRF-8患者的总生存率更好(统计学上不显著)。这些结果表明,DL可以根据这些因素的表达进行分类。接下来,为了鉴定单个肿瘤细胞中这些因子目录的蛋白,免疫组织化学进行了挑战。然而,由于缺乏针对人IRF-8的良好抗体,因此无法获得明确的结果。近年来,研究发现IRF-4和IRF-8与bc 1 -2在恶性血液病的发病过程中有协同作用。Bcl-2是一种凋亡因子,与IgH形成嵌合体基因,通常在FL中发现易位(14; 8)。为了阐明这种易位在DL中的作用,对35例高危DL患者的样本进行了bcl 2/IgH的FISH和bcl 1 -2蛋白的免疫组化。在死亡病例标本中,Bc 12/IgH融合阳性率为57.1%。另一方面,在71.4%的存活者的肿瘤细胞中既未检测到bc 1 - 2/IgH融合,也未检测到bc 1 -2表达,这表明易位(14; 18)在难治性DL中起关键作用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Management of refractory and relapsed Hodgkin lymphoma
难治性和复发性霍奇金淋巴瘤的治疗
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:Tsujimura H;Takagi T
- 通讯作者:Takagi T
Fatal fulminant Clostridium difficile colitis during CHOP therapy for lymphoma : an autopsy case
淋巴瘤 CHOP 治疗期间致命的暴发性艰难梭菌结肠炎:尸检病例
- DOI:
- 发表时间:2007
- 期刊:
- 影响因子:0
- 作者:Hideki Tsujimura;et. al.
- 通讯作者:et. al.
Fatal fulminant Clostridium diffcile colitis during CHOP therapy for lymphoma: an autopsy case
淋巴瘤 CHOP 治疗期间致命的暴发性艰难梭菌结肠炎:尸检病例
- DOI:
- 发表时间:2007
- 期刊:
- 影响因子:0
- 作者:Hideki Tsujimura;et. al.
- 通讯作者:et. al.
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
HIDEKI Tsujimura其他文献
HIDEKI Tsujimura的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Elucidation of Novel Therapeutic Targets for Primary Intraocular Malignant Lymphoma Based on Analysis of B Cells within Tertiary Lymphoid Structures
基于三级淋巴结构内 B 细胞的分析阐明原发性眼内恶性淋巴瘤的新治疗靶点
- 批准号:
23K15921 - 财政年份:2023
- 资助金额:
$ 1.77万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Realization of Quantitatively Evaluation Criteria for Atypia based on Morphological Features of Cellular Tissue towards the Construction of Morphology in Malignant Lymphoma
实现基于细胞组织形态特征的异型性定量评价标准,构建恶性淋巴瘤形态学
- 批准号:
23KJ1141 - 财政年份:2023
- 资助金额:
$ 1.77万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Development of novel therapeutic approach for refractory anemia and malignant lymphoma by targeting ferroptosis suppressor protein-1
以铁死亡抑制蛋白-1为靶点开发难治性贫血和恶性淋巴瘤的新治疗方法
- 批准号:
22KK0270 - 财政年份:2023
- 资助金额:
$ 1.77万 - 项目类别:
Fund for the Promotion of Joint International Research (Fostering Joint International Research (A))
Comprehensive elucidation of molecular pathogenesis based on genetic abnormalities in malignant lymphoma
基于恶性淋巴瘤基因异常全面阐明分子发病机制
- 批准号:
21H05051 - 财政年份:2021
- 资助金额:
$ 1.77万 - 项目类别:
Grant-in-Aid for Scientific Research (S)
Evaluation of minimal residual disease by liquid biopsy in malignant lymphoma for precise therapeutic stratification.
通过液体活检评估恶性淋巴瘤的微小残留病,以进行精确的治疗分层。
- 批准号:
21K08407 - 财政年份:2021
- 资助金额:
$ 1.77万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Investigation for spontaneous regression of malignant lymphoma
恶性淋巴瘤自然消退的研究
- 批准号:
21K16260 - 财政年份:2021
- 资助金额:
$ 1.77万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Exploring association of ganglioside in cutaneous malignant lymphoma with tumor immunology
探索皮肤恶性淋巴瘤中神经节苷脂与肿瘤免疫学的关系
- 批准号:
21K08300 - 财政年份:2021
- 资助金额:
$ 1.77万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Functional role of PD-L1 alteration in the pathogenesis of malignant lymphoma
PD-L1改变在恶性淋巴瘤发病机制中的功能作用
- 批准号:
20K17415 - 财政年份:2020
- 资助金额:
$ 1.77万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Eludation of organ tropism from the diversity of malignant lymphoma and its application to novel treatment
从恶性淋巴瘤的多样性中揭示器官向性及其在新治疗中的应用
- 批准号:
20K08751 - 财政年份:2020
- 资助金额:
$ 1.77万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
A development of a gene mutations-targeted novel therapy in malignant lymphoma
恶性淋巴瘤基因突变靶向新疗法的开发
- 批准号:
20K17409 - 财政年份:2020
- 资助金额:
$ 1.77万 - 项目类别:
Grant-in-Aid for Early-Career Scientists